Novartis
Eisai partners with Novartis in renal cell carcinoma collaboration
June 3, 2016Medical Communications, Sales and Marketing Afinitor, Eisai, Lenvima, Novartis, US, everolimus, lenvatinib mesylate
Eisai (TYO: 4523) has announced that it has entered into a partnership with Novartis Pharmaceuticals to collaborate on commercial and …
Novartis’ Afinitor gets EU approval to treat cancerous gastrointestinal or lung tumors
June 2, 2016Research and Development, Sales and Marketing Afinitor, Cancer, European Commission, Novartis, regulation
Swiss drugmaker Novartis (VTX: NOVN) on Thursday said the European Commission has approved its Afinitor (everolimus) to treat cancerous gastrointestinal …
Phase III trials to start in Novartis/Genmab multiple sclerosis collaboration
June 2, 2016Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, ofatumumab, phase III
Genmab (NASDAQ: GEN) has announced that its collaboration partner, Novartis, is set to initiate Phase III trials for ofatumumab in …
Novartis’ heart failure drug Entresto gets top US, EU recommendation
May 23, 2016Research and Development, Sales and Marketing Ernesto, Novartis, heart failure, regulation
Swiss drugmaker Novartis (VTX: NOVN) said its heart failure drug Entresto (sacubitril/ valsartan) has secured top recommendations in the US …
Nice backs Novartis’ lung cancer drug
May 20, 2016NHS, NICE, Novartis, ceritinib, lung cancer, recommendation, regulation
The National Institute for Health and Care Excellence (Nice) has recommended Novartis’ (VTX: NOVN) Ceritinib (zykadia) as a treatment for …
Breast cancer trial stopped after meeting primary endpoint early
May 18, 2016Research and Development LEE011, Novartis, breast cancer, progression free survival, ribociclib
A Phase III trial evaluating LEE011 (ribociclib), developed by Novartis, has been stopped early after a recommendation from an independent …
Novartis splits pharmaceuticals division into two business units
May 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing Novartis, epstein, new division
Novartis has announced internal structural changes that it says will “focus” its pharmaceuticals division by creating two business units, Novartis …
Novartis says trials show its COPD drug more effective versus GSK’s Seretide
May 16, 2016Research and Development, Sales and Marketing GSK, Novartis, drug trial, research
Swiss drug firm Novartis (VTX: NOVN) said its asthma drug showed efficacy over GlaxoSmithKline’s (LSE: GSK) medicine in a comparison …
Afinitor receives EU recommendation to treat rare lung cancer
April 29, 2016Manufacturing and Production, Research and Development, Sales and Marketing Afinitor, Novartis
Novartis has received a recommendation from the Committee for Medicinal Products for Human Use at the European Medicines Agency for …
Novartis’ two cancer drugs get NICE backing as combination treatment for skin cancer
April 29, 2016Medical Communications NICE, Novartis, combination therapy, regulation, skin cancer
The National Institute for Health and Care Excellence (NICE) on Friday backed a combination therapy for skin cancer comprising two …
NICE gives green light to Novartis’s heart drug Entresto
April 27, 2016Research and Development, Sales and Marketing Entresto, NHS, NICE, Novartis, benefit, heart failure, patients
NICE has published final guidance recommending heart failure drug Entresto (sacubritil/valsartan). The drug, developed by Novartis, has performed well in …
Novartis’ Ilaris gets US FDA breakthrough therapy designation to treat fever syndromes
April 27, 2016Business Services, Research and Development Breakthrough Therapy Designation, Novartis, US FDA, periodic fever syndromes
Novartis (VTX: NOVN) on Wednesday said its drug to treat three rare types of periodic fever syndromes has been granted …
Novartis exploring almost $14-billion stake sale in Roche – reports
April 26, 2016Manufacturing and Production, Sales and Marketing Financial, Merger & Acquisition, Novartis, Roche, Stake sale
Swiss pharma firm Novartis (VTX: NOVN) maybe looking at options to sell its one-third stake in cancer drugmaker Roche’s (VTX: …
Novartis muscular drug fails in Phase III trials
April 22, 2016Medical Communications, Research and Development FDA, Novartis, bimagrumab, breakthrough, morphosys, muscular, phase III
A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint …
Novartis drug Afinitor significantly reduces seizures in TSC patients
April 21, 2016Research and Development Afinitor, Novartis, Tuberous Sclerosis Complex, drug, seizure, seizures, tsc
Novartis (SIX: NOVN) has announced the results from a Phase III clinical trial which shows that Afinitor (everolimus) significantly reduced …
Latest content
FibroFind appoints Lee Borthwick as CEO
